[Payment of Filing Fee (Check the appropriate box): x No fee required. o Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. 1) Title of each class of securities to which transaction applies:]
[Payment of Filing Fee (Check the appropriate box): x No fee required. o Feemputed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. 1) Title of each class of securities to which transaction applies: 2)gregate number of securities to which transaction applies: 3) 4) Proposed maximumgregate value of transaction:]
[Payment of Filing Fee (Check the appropriate box): x No fee required. o Feemputed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. 1) Title of each class of securities to which transaction applies: 2)gregate number of securities to which transaction applies: 3) 4) Proposed maximumgregate value of transaction:]
[R E C I T A L S NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto hereby agree as follows: 1. Amendment (a) deleting Sections 3(e) and (f) and replacing it with the following: Issuance of Additional Shares of Common Stock subsections (a) through (d) of this Section 3] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT November 30, 2010 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co., Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction of incorporation) (IRS Employer Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 Section 8 –]
[November 23, 2010 Division of Corporate Finance 100 F. Street, N.E. Attn: Frank Wyman Re: Tianyin Pharmaceutical Co., Inc. Form 10-K for the Fiscal Year Ended June 30, 2009 Form 10-Q for Quarterly Period Ended December 31, 2009 File No. 001-34189 Dear Mr. Wyman: This letter is provided in response to your letter dated October 29, 2010, regarding the above-referenced]
[November 23, 2010 Division of Corporate Finance 100 F. Street, N.E. Attn: Frank Wyman Re: Tianyin Pharmaceutical Co., Inc. Form 10-K for the Fiscal Year Ended June 30, 2009 Form 10-Q for Quarterly Period Ended December 31, 2009 File No. 001-34189 Dear Mr. Wyman: This letter is provided in response to your letter dated October 29, 2010, regarding the above-referenced]
[NEWS RELEASE Skystar Bio-Pharmaceutical Announces Record Organic Revenues of $18.5 Million For Third Quarter Fiscal Year 2010 - Company reiterates fiscal 2010 guidance of $45.5 Million to $47.5 Million - XI’AN, CHINA – November 16, 2010 -- - Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) ("Skystar" or the "Company"), Third Quarter 2010 Highlights · Revenue increases 45% YoY to record $18.5 million ·]
[NEWS RELEASE Skystar Bio-Pharmaceutical Announces Record Organic Revenues of $18.5 Million For Third Quarter Fiscal Year 2010 - Company reiterates fiscal 2010 guidance of $45.5 Million to $47.5 Million - XI’AN, CHINA – November 16, 2010 -- - Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) ("Skystar" or the "Company"), Third Quarter 2010 Highlights · Revenue increases 45% YoY to record $18.5 million ·]
[Tianyin Reports Record First Quarter Fiscal Year 2011 Financial Results Press Release Source Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine, branded generics and other pharmaceuticals announced financial results for the first quarter of Fiscal Year 2011. First quarter fiscal year 2011 ending September 30, 2010 financial highlights] [Tianyin Pharmaceutical, Inc. First Quarter Fiscal Year 2011 Earnings Results November 11, 2010 Operator: Ladies and gentlemen, thank you for standing by and welcome to the Tianyin Pharmaceutical, Inc. Fiscal Year 2010 Earnings conference call. During today’s presentation all parties will be in a listen-only mode. Following the presentation the conference will be open for questions. If you have a] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT November 11, 2010 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co., Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction of incorporation) (IRS Employer Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 Section 7 –]
[Sinovac Reports Unaudited Third Quarter 2010 Financial Results - Conference call scheduled for Monday, November 15, 2010 at 8:00 AM EST Beijing November 15, 2010 Sinovac Biotech Ltd. ( NASDAQ: SVA), a leading provider of biopharmaceutical products in China , announc ed today its un audited financial results for the three-month and nine-month periods ended September 30,] [1 -32371 SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, Peoples Republic of China Form 20-F x Form 40-F o o o SINOVAC BIOTECH LTD.]
